- Home
- MDCX vs LSTA Comparison
MDCX vs LSTA Comparison
Compare MDCX & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MDCX | LSTA |
|---|---|---|
| Founded | 2008 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Misc Health and Biotechnology Services |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.4M | 20.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MDCX | LSTA |
|---|---|---|
| Price | $1.89 | $2.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $23.50 | $23.50 |
| AVG Volume (30 Days) | ★ 357.4K | 23.8K |
| Earning Date | 11-14-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,070,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.68 | $1.81 |
| 52 Week High | $8.94 | $4.20 |
Technical Indicators
Market Signals| Indicator | MDCX | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 42.20 | 46.57 |
| Support Level | $1.87 | $1.85 |
| Resistance Level | $2.25 | $2.15 |
| Average True Range (ATR) | 0.19 | 0.14 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 34.15 | 59.53 |
Price Performance
Historical ComparisonAbout MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.